Skip to content
Open access

Can Multidrug‐Resistant and Extensively Drug‐Resistant Tuberculosis be Treated More Successfully?

Sep 2026 · Public Health Challenges · Vol 5 · 0 citations · 30 references
Medicine

Abstract

ABSTRACT Background Signs and symptoms of tuberculosis (TB) are a result of a disturbed balance between Mycobacterium tuberculosis and the patient's tolerance to its pathogenic properties. Pharmacological treatments elicit the evolution of drug resistance, and there is a need to consider alternative treatment methods. We performed a statistical analysis of World Health Organization (WHO) data, combined with an analysis of old medical records, aimed at suggesting a new treatment. Methods Data from the WHO for all countries worldwide (N = 215) on the epidemiology of all TB cases, human immunodeficiency virus (HIV)‐related TB, multidrug‐resistant TB (MDR) and extensively drug‐resistant TB (XDR) in 2012–2022 contain prevalence, success rate of treatment, mortality and numbers of failed treatments and patients lost‐to‐follow‐up. Data on success rates in old ‘sanatoria treatment’, widespread before the 1940s, were used to predict hypothetical success rates of drug‐resistant cases if sanatoria treatment were added to treatment regimes. Results After 2012, the number of MDR and XDR cases increased faster than the total number of TB cases, as did their proportions among the total. Success rates of MDR (∼70%) and XDR (around 60%) treatments would hypothetically increase to around 90%, when supplemented by sanatoria treatment success. Conclusions Adding treatments for increasing tolerance to TB infection to the current pharmacological treatments may improve outcomes.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.